Raxibacumab, CAS 565451-13-0

Product Description: Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research[1][2].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Cui X, et.al. Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J Infect Dis. 2005 Feb 1;191(3):422-34. /[2]Mazumdar S. Raxibacumab. MAbs.2009 Nov-Dec;1(6):531-8. /[3]Kummerfeldt CE. Raxibacumab: potential role in the treatment of inhalational anthrax. Infect Drug Resist. 2014 Apr 29;7:101-9.

CAS Number: 565451-13-0

Molecular Weight: N/A

Compound Purity: 98.88

Research Area: Infection

Solubility: H2O

Target: Bacterial

• Artikelnummer: MEXHY-P9957-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9957-1
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated